XML 105 R53.htm IDEA: XBRL DOCUMENT v3.19.3
Capitalization And Short-Term Borrowings (Narrative) (Details)
3 Months Ended 12 Months Ended
Aug. 17, 2018
USD ($)
Sep. 30, 2019
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
$ / shares
shares
Sep. 30, 2018
USD ($)
$ / shares
shares
Sep. 30, 2017
USD ($)
$ / shares
shares
Sep. 07, 2018
USD ($)
Sep. 27, 2017
USD ($)
Debt Instrument [Line Items]              
Issue shares of common stock for the Direct Stock Purchase and Dividend Reinvestment Plan | shares     0        
Common stock issued for 401(k) plans | shares     0        
Common stock shares issued due to SARs exercises | shares     126,879        
Shares tendered | shares     159,413        
Share-Based Payment Expense     $ 19,500,000 $ 14,200,000 $ 10,800,000    
Tax benefit related to stock-based compensation expense     3,800,000 3,400,000 4,400,000    
Capitalized stock-based compensation costs     100,000 100,000 100,000    
Tax benefit from stock-based compensation exercises and vestings     3,200,000        
Unamortized Debt Expense   $ 14,005,000 14,005,000 15,975,000      
Gain (Loss) on Extinguishment of Debt       1,000,000.0      
Net proceeds from issuance of long-term debt     0 295,020,000 $ 295,151,000    
Principal amounts of long-term debt maturing in 2020   0 0        
Principal amounts of long-term debt maturing in 2021   0 0        
Principal amounts of long-term debt maturing in 2022   500,000,000.0 500,000,000.0        
Principal amounts of long-term debt maturing in 2023   549,000,000.0 549,000,000.0        
Principal amounts of long-term debt maturing in 2024   0 0        
Principal amounts of long-term debt maturing after 2024   1,100,000,000.0 1,100,000,000.0        
Commercial paper, outstanding   $ 55,200,000 $ 55,200,000 0      
Weighted average interest rate on commercial paper   2.50% 2.50%        
Short-term notes payable outstanding   $ 0 $ 0 $ 0      
Committed credit facility maximum debt to capitalization ratio     0.65        
Ceiling Test Impairment Adjustment   50.00% 50.00%        
Ceiling Test Impairment Maximum Adjustment   $ 250,000,000 $ 250,000,000        
Debt to capitalization ratio     0.51        
Additional borrowing   1,780,000,000 $ 1,780,000,000        
Aggregated indebtedness     $ 40,000,000.0        
Maximum debt increase under existing indenture covenants   $ 1,020,000,000.00          
Preferred stock, shares authorized | shares   10,000,000 10,000,000        
Preferred stock par value | $ / shares   $ 1 $ 1        
Percentage of Long-Term Debt issued under 1974 Indenture     4.60%        
Stock Appreciation Rights (SARs) [Member]              
Debt Instrument [Line Items]              
Number of Shares Granted | shares     0 0 0    
Total intrinsic value of SAR's exercised     $ 7,200,000 $ 4,400,000 $ 1,600,000    
Number of Awards Vested | shares     0 0 5,000    
Equity instruments other than options, vested in period, total fair value         $ 100,000    
Restricted Share Awards [Member]              
Debt Instrument [Line Items]              
Number of Shares Granted | shares     0 0 0    
Weighted Average Fair Value per Award Granted | $ / shares     $ 0        
Number of Awards Vested | shares     0        
Unrecognized compensation expense   $ 100,000 $ 100,000        
Unrecognized compensation expense recognized weighted average period     1 year 1 month 6 days        
Non-Performance Based Restricted Stock Units (RSUs) [Member]              
Debt Instrument [Line Items]              
Number of Shares Granted | shares     123,939 89,672 87,143    
Weighted Average Fair Value per Award Granted | $ / shares     $ 49.40 $ 51.23 $ 52.13    
Number of Awards Vested | shares     80,354        
Unrecognized compensation expense   6,100,000 $ 6,100,000        
Unrecognized compensation expense recognized weighted average period     2 years 3 months 18 days        
Performance Shares [Member]              
Debt Instrument [Line Items]              
Common stock issued | shares     281,882        
Number of Shares Granted | shares     244,734 208,588 184,148    
Weighted Average Fair Value per Award Granted | $ / shares     $ 55.67 $ 50.95 $ 56.39    
Number of Awards Vested | shares     281,882        
Unrecognized compensation expense   8,700,000 $ 8,700,000        
Unrecognized compensation expense recognized weighted average period     1 year 8 months 12 days        
Restricted Stock Units (RSUs) [Member]              
Debt Instrument [Line Items]              
Common stock issued | shares     80,354        
Board Of Directors [Member]              
Debt Instrument [Line Items]              
Common stock issued | shares     28,771        
3.95% Notes Due September 15, 2027 [Member]              
Debt Instrument [Line Items]              
Long-term debt, face value             $ 300,000,000.0
Long-term debt, interest rate             3.95%
4.75% Notes Due September 1, 2028 [Member]              
Debt Instrument [Line Items]              
Long-term debt, face value $ 300,000,000.0            
Long-term debt, interest rate 4.75%            
Net proceeds from issuance of long-term debt $ 295,000,000.0            
8.75% Notes Due May 2019 [Member]              
Debt Instrument [Line Items]              
Long-term debt, face value           $ 250,000,000.0  
Long-term debt, interest rate           8.75%  
Debt Instrument redeemed       $ 259,500,000      
Unamortized Debt Expense       8,500,000      
6.50% Notes Due April 2018 [Member]              
Debt Instrument [Line Items]              
Long-term debt, face value       $ 300,000,000.0      
Long-term debt, interest rate       6.50%      
Debt Instrument redeemed       $ 307,000,000.0      
Indenture From 1974 [Member]              
Debt Instrument [Line Items]              
Carrying Amount   99,000,000.0 $ 99,000,000.0        
Commercial Paper [Member]              
Debt Instrument [Line Items]              
Commercial paper available   500,000,000.0 500,000,000.0        
Fourth Amended & Restated Credit Agreement [Member]              
Debt Instrument [Line Items]              
Line of Credit Facility, Maximum Borrowing Capacity   $ 750,000,000.0 $ 750,000,000.0        
2020 [Member] | Non-Performance Based Restricted Stock Units (RSUs) [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     87,835        
2020 [Member] | Performance Shares [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     173,454        
2021 [Member] | Restricted Share Awards [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     20,000        
2021 [Member] | Non-Performance Based Restricted Stock Units (RSUs) [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     76,146        
2021 [Member] | Performance Shares [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     170,526        
2022 [Member] | Non-Performance Based Restricted Stock Units (RSUs) [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     67,525        
2022 [Member] | Performance Shares [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     178,534        
2023 [Member] | Non-Performance Based Restricted Stock Units (RSUs) [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     33,831        
2024 [Member] | Non-Performance Based Restricted Stock Units (RSUs) [Member]              
Debt Instrument [Line Items]              
Non-vested stock-based compensation lapse | shares     16,270